679 related articles for article (PubMed ID: 23809767)
1. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G
Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767
[TBL] [Abstract][Full Text] [Related]
2. Expression of orphan nuclear receptor NR4A2 in gastric cancer cells confers chemoresistance and predicts an unfavorable postoperative survival of gastric cancer patients with chemotherapy.
Han Y; Cai H; Ma L; Ding Y; Tan X; Chang W; Guan W; Liu Y; Shen Q; Yu Y; Zhang H; Cao G
Cancer; 2013 Oct; 119(19):3436-45. PubMed ID: 23821160
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling-derived immunohistochemistry signature with high prognostic value in colorectal carcinoma.
Chang W; Gao X; Han Y; Du Y; Liu Q; Wang L; Tan X; Zhang Q; Liu Y; Zhu Y; Yu Y; Fan X; Zhang H; Zhou W; Wang J; Fu C; Cao G
Gut; 2014 Sep; 63(9):1457-67. PubMed ID: 24173294
[TBL] [Abstract][Full Text] [Related]
4. C-reactive protein is a negative independent factor in patients with stage IV colorectal cancer undergoing oxaliplatin-based chemotherapy.
Fukuchi M; Kuwabara K; Tsuji Y; Baba H; Ishibashi K; Chika N; Hatano S; Matsuzawa T; Kumamoto K; Kumagai Y; Mochiki E; Ishida H
Anticancer Res; 2013 Nov; 33(11):5051-5. PubMed ID: 24222149
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.
Chang MH; Lee IK; Si Y; Lee KS; Woo IS; Byun JH
Cancer Chemother Pharmacol; 2011 Aug; 68(2):317-23. PubMed ID: 20972872
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for disease-free survival after preoperative chemotherapy followed by curative resection in patients with colorectal cancer harboring hepatic metastasis: a single-institute, retrospective analysis in Asia.
Yi JH; Kim H; Jung M; Shin SJ; Choi JS; Choi GH; Baik SH; Min BS; Kim NK; Ahn JB
Oncology; 2013; 85(5):283-9. PubMed ID: 24217184
[TBL] [Abstract][Full Text] [Related]
7. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis.
Kim HR; Min BS; Kim JS; Shin SJ; Ahn JB; Rho JK; Kim NK; Rha SY
Oncology; 2011; 81(3-4):175-83. PubMed ID: 22057187
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy.
Huang MY; Tsai HL; Lin CH; Huang CW; Ma CJ; Huang CM; Chai CY; Wang JY
J Surg Oncol; 2013 Dec; 108(7):457-64. PubMed ID: 23996617
[TBL] [Abstract][Full Text] [Related]
10. Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil–based chemotherapy.
Collura A; Lagrange A; Svrcek M; Marisa L; Buhard O; Guilloux A; Wanherdrick K; Dorard C; Taieb A; Saget A; Loh M; Soong R; Zeps N; Platell C; Mews A; Iacopetta B; De Thonel A; Seigneuric R; Marcion G; Chapusot C; Lepage C; Bouvier AM; Gaub MP; Milano G; Selves J; Senet P; Delarue P; Arzouk H; Lacoste C; Coquelle A; Bengrine-Lefèvre L; Tournigand C; Lefèvre JH; Parc Y; Biard DS; Fléjou JF; Garrido C; Duval A
Gastroenterology; 2014 Feb; 146(2):401-11.e1. PubMed ID: 24512910
[TBL] [Abstract][Full Text] [Related]
11. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.
van Geelen CM; Westra JL; de Vries EG; Boersma-van Ek W; Zwart N; Hollema H; Boezen HM; Mulder NH; Plukker JT; de Jong S; Kleibeuker JH; Koornstra JJ
J Clin Oncol; 2006 Nov; 24(31):4998-5004. PubMed ID: 17075118
[TBL] [Abstract][Full Text] [Related]
13. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group.
Giacchetti S; Bjarnason G; Garufi C; Genet D; Iacobelli S; Tampellini M; Smaaland R; Focan C; Coudert B; Humblet Y; Canon JL; Adenis A; Lo Re G; Carvalho C; Schueller J; Anciaux N; Lentz MA; Baron B; Gorlia T; Lévi F;
J Clin Oncol; 2006 Aug; 24(22):3562-9. PubMed ID: 16877722
[TBL] [Abstract][Full Text] [Related]
14. FOLFOX as adjuvant chemotherapy after curative resection of distant metastases in patients with colorectal cancer.
Nozawa H; Kitayama J; Sunami E; Saito S; Kanazawa T; Kazama S; Yazawa K; Kawai K; Mori K; Nagawa H
Oncology; 2011; 80(1-2):84-91. PubMed ID: 21677451
[TBL] [Abstract][Full Text] [Related]
15. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
[TBL] [Abstract][Full Text] [Related]
16. Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea.
Kim JY; Kim YJ; Lee KW; Lee JS; Kim DW; Kang SB; Lee HS; Jang NY; Kim JS; Kim JH
Jpn J Clin Oncol; 2013 Feb; 43(2):132-8. PubMed ID: 23204187
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of microsatellite instability in colorectal cancer patients treated with adjuvant FOLFOX.
Des Guetz G; Lecaille C; Mariani P; Bennamoun M; Uzzan B; Nicolas P; Boisseau A; Sastre X; Cucherousset J; Lagorce C; Schischmanoff PO; Morere JF
Anticancer Res; 2010 Oct; 30(10):4297-301. PubMed ID: 21036755
[TBL] [Abstract][Full Text] [Related]
18. Cyclooxygenase-2 inhibitors down-regulate osteopontin and Nr4A2-new therapeutic targets for colorectal cancers.
Zagani R; Hamzaoui N; Cacheux W; de Reyniès A; Terris B; Chaussade S; Romagnolo B; Perret C; Lamarque D
Gastroenterology; 2009 Oct; 137(4):1358-66.e1-3. PubMed ID: 19549529
[TBL] [Abstract][Full Text] [Related]
19. Deleted in colorectal cancer protein expression as a possible predictor of response to adjuvant chemotherapy in colorectal cancer patients.
Gal R; Sadikov E; Sulkes J; Klein B; Koren R
Dis Colon Rectum; 2004 Jul; 47(7):1216-24. PubMed ID: 15148649
[TBL] [Abstract][Full Text] [Related]
20. Survival impact of surgical resection of primary tumor in patients with stage IV colorectal cancer: results from a large population-based cohort study.
Ahmed S; Leis A; Fields A; Chandra-Kanthan S; Haider K; Alvi R; Reeder B; Pahwa P
Cancer; 2014 Mar; 120(5):683-91. PubMed ID: 24222180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
